Benefits
High-Purity, Bioavailable Form
pTeroWhite® delivers ~99% trans-pterostilbene, the methylated resveratrol analog whose two methoxy groups improve lipophilicity, slow first-pass metabolism, and extend half-life. This supports more reliable plasma exposure than equivalent resveratrol, making it a practical antioxidant building block.
Antioxidant and Cellular Defense Support
Pterostilbene helps activate the body's own Nrf2-linked antioxidant response and may help maintain healthy oxidative balance. This broad antioxidant profile is the most consistent rationale across its metabolic, cognitive, and longevity uses.
Metabolic and Cardiovascular Support
A controlled human trial found pterostilbene may support healthy blood pressure that is already within or near the normal range. Effects on cholesterol were mixed, so it is best viewed as general metabolic support rather than a lipid-lowering agent.
Cognitive and Longevity Interest
Preclinical work links pterostilbene to SIRT1 signaling, neuroprotection, and healthy aging pathways, and it is a common component of NAD+/sirtuin longevity stacks. Human cognitive evidence is preliminary, so benefits are framed cautiously.
Anti-Inflammatory Profile
Pterostilbene helps modulate NF-κB-driven inflammatory signaling in laboratory models, complementing its antioxidant actions. This may support a healthy inflammatory balance as part of an overall antioxidant-focused regimen.
Mechanism of action
Improved Pharmacokinetics vs Resveratrol
Two methoxy groups (replacing resveratrol's hydroxyls) make pterostilbene more lipophilic, improving membrane penetration and resistance to first-pass metabolism. The result is higher oral bioavailability and a longer plasma half-life for the same stilbene core.
Nrf2 Antioxidant Pathway Activation
Pterostilbene activates the Nrf2 transcription factor, upregulating endogenous antioxidant enzymes such as superoxide dismutase, catalase, and glutathione-synthesizing enzymes — an adaptive cellular defense response.
SIRT1 Signaling
Like resveratrol, pterostilbene engages SIRT1 deacetylase signaling implicated in mitochondrial biogenesis and glucose handling. Better bioavailability is the proposed advantage, though clinical confirmation of longevity outcomes is lacking.
PPAR-alpha and Lipid Metabolism
Pterostilbene modulates PPAR-alpha, a nuclear receptor governing fatty-acid oxidation and lipid handling, which may underlie its metabolic effects observed in animal models.
Clinical trials
Randomized, double-blind, placebo-controlled trial of pterostilbene (125 mg twice daily or 50 mg twice daily) alone or with grape extract vs placebo in 80 adults with elevated cholesterol over 6–8 weeks.
80 adults with hypercholesterolemia.
High-dose pterostilbene was associated with modest reductions in systolic and diastolic blood pressure. LDL cholesterol rose with pterostilbene used alone but not when combined with grape extract, so the overall metabolic picture was mixed and warrants monitoring in people with lipid concerns.
Safety analysis from the same prospective, randomized, double-blind, placebo-controlled trial, evaluating hepatic, renal, and glucose markers and self-reported adverse effects at doses up to 250 mg/day.
80 adults; up to 250 mg/day for 6–8 weeks.
Pterostilbene was generally well tolerated up to 250 mg/day with no adverse effects on liver, kidney, or glucose markers and no major self-reported adverse reactions. This established a reassuring short-term safety profile for the dose range used in supplements.